Respuesta :
We discovered that pathway-based signatures derived from tumor samples collected during treatment are not only indicative of anti-PD1 blockade response in patients with metastatic melanoma, but also associated with clinical outcomes.
Both genomic and transcriptome profiles have been developed to forecast how immune checkpoint blockade (ICB) medications may affect metastatic melanoma; however, the majority of these signatures are taken from pre-treatment biopsy data. Using transcriptome data and clinical information from a sizable dataset of metastatic melanoma patients treated with anti-PD1-based medicines as the training set, we construct pathway-based super signatures in pre-treatment (PASS-PRE) and on-treatment (PASS-ON) tumor tissues. With area under the curve (AUC) values of 0.45-0.69 and 0.85-0.89, respectively, both the PASS-PRE and PASS-ON signatures are verified in three separate datasets of metastatic melanoma as the validation set.
learn more about tumor specimens here:
https://brainly.com/question/4188942
#SPJ4
